Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo, Kenshi Suzuki, Stefan Knop, Chantal Doyen, Paulo Lúcio, Zsolt Nagy, Luděk Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Sung‐Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Shinsuke Iida, Joan Bladé, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Anupa Kudva, Ming Qi, Jesús F. San Miguel
Topics & Concepts
MelphalanMedicineBortezomibHazard ratioPrednisoneInternal medicineDaratumumabMultiple myelomaGastroenterologyOncologySurgeryConfidence intervalMultiple Myeloma Research and TreatmentsAcute Myeloid Leukemia ResearchMultiple and Secondary Primary Cancers